Continuous dopaminergic stimulation: state of the art and outlook

  • R. Horowski
  • C. D. Marsden
  • J. A. Obeso
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)


Therapy with L-Dopa was a major break-through in the treatment of Parkinson’s disease. It was an important precedent, and a stimulus for research in this and other fields of neurology. Initial side effects associated with this drug were overcome by refining the treatment schedule and by additional drugs inhibiting the peripheral conversion of L-Dopa to dopamine.


Dopamine Agonist Motor Fluctuation Central Side Effect Psychiatric Side Effect Continuous Dopaminergic Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W, Hornykiewicz O (1961) Der L-3,4-Dihydroxyphenylalanin (= Dopa)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–789PubMedGoogle Scholar
  2. Bittkau S, Przuntek H (1986) Psychosis and the lisuride pump. Lancet 2: 349 (letter)Google Scholar
  3. Burns RS, Calne DB (1983) Disposition of dopaminergic ergot compounds following oral administration. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 153–160Google Scholar
  4. Critchley P, Grandas Perez F, Quinn N, Coleman P, Parkes D, Marsden CD (1986) Psychosis and the lisuride pump. Lancet 2: 349 (letter)Google Scholar
  5. Dorow R, Graf KJ, Nieuweboer B, Horowski R (1980) Intravenous lisuride: a new tool for testing responsiveness to dopamine agonists and neuroendocrine function. Acta Endocrinol [Suppl] (Copenh) 234: 9Google Scholar
  6. Horowski R (1983) Pharmacological effects of lisuride and their potential role in further research. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 127–139Google Scholar
  7. Horowski R ( 1986 a) Pharmacology of the dopamine agonist lisuride and its potential in the treatment of parkinsonism. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 24–35Google Scholar
  8. Horowski R (1986 b) Psychiatric side-effects of high-dose lisuride therapy in Parkinsonism. Lancet 2: 510 (letter)Google Scholar
  9. Obeso J A, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470PubMedCrossRefGoogle Scholar
  10. Obeso JA, Grandas, F, Vaamonde J, Luquin MR, Martinez-Lage JM (1987) Apomorphine infusion for motor fluctuations in Parkinson’s disease. Lancet 1: 1376–1377PubMedCrossRefGoogle Scholar
  11. Quinn NP, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson’s disease: Response to intravenous infusion of levodopa. Lancet 2: 412–415PubMedCrossRefGoogle Scholar
  12. Ruggieri S, Stocchi F, Agnoli A (1986) Lisuride infusion pump for Parkinson’s disease. Lancet 2: 348–349 (letter)CrossRefGoogle Scholar
  13. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in Parkinsonism with Clozapine and Fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64CrossRefGoogle Scholar
  14. Schwab RS, Amadori LV, Lettoni J Y (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 76: 251Google Scholar
  15. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148PubMedCrossRefGoogle Scholar
  16. Stibe C, Lees A, Stern G (1987) Subcutaneous infusion of apomorphine and lisuride in the treatment of Parkinsonian on-off-fluctuations. Lancet 1: 871PubMedCrossRefGoogle Scholar
  17. Strian F, Micheler E, Benkert O (1972) Tremor inhibition in Parkinson syndrome after apomorphine administration under L-Dopa and decarboxylase—inhibitor basic therapy. Pharmacopsychiatry 5: 198–205CrossRefGoogle Scholar
  18. Struppler A (1953) Die therapeutische Beeinflußbarkeit des Tremors. Med Monatsschr 73: 157–160Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • R. Horowski
    • 1
  • C. D. Marsden
    • 2
  • J. A. Obeso
    • 3
  1. 1.Clinical ResearchSchering AGBerlin/BergkamenGermany
  2. 2.University Department of Clinical NeurologyInstitute of NeurologyLondonUK
  3. 3.Clinica Universitaria, Departmento de NeurologiaUniversidad de NavarraPamplonaSpain

Personalised recommendations